Company: LCTX
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0000950170-25-060090
Chunk: 38

Company: Lineage Cell Therapeutics, Inc.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 38
---
 our named executive officers (commonly called the “say-on-pay” vote) at our 2024 annual meeting of shareholders showed that approximately 96% of the votes cast “FOR” or “AGAINST” on the “say-on-pay” vote approved the compensation of our named executive officers during 2023. Our Compensation Committee carefully evaluated and considered the results of this advisory vote and concluded that our shareholders generally supported our executive compensation program and we did not make significant changes to our executive compensation program for 2024. Our Compensation Committee expects to continue to consider the outcome of our “say-on-pay” votes and our shareholders’ views when making future compensation decisions for our named executive officers.

<div align='center'>-27-</div>

PAY VERSUS PERFORMANCE

The disclosure included in this section is prescribed by SEC rules and does not necessarily align with how Lineage or our Board or the Compensation Committee view the link between Lineage’s performance and named executive officer pay, and neither our Board nor the Compensation Committee uses CAP (as defined below) as the basis for making compensation decisions. For additional information about our pay-for-performance philosophy and how we align executive compensation with performance, please see the section titled “Executive Compensation” above.

Required Tabular Disclosure of Pay Versus Performance

The following table reports the compensation of our Chief Executive Officer, who is our principal executive officer (“PEO”), and the average compensation of our other named executive officers (“Non-PEO NEOs”) as reported in the Summary Compensation Table (the “SCT”) in the section titled “Executive Compensation,” above, for the past three fiscal years (“FYs”), as well as the Compensation Actually Paid (“CAP”) as calculated under the SEC pay-versus-performance disclosure requirements.

| Year 
 (a)  |     | Summary      
 Compensation 
 Table Total  
 for PEO(1)   
 (b)          |           |     | Compensation  
 Actually Paid 
 to PEO(2)     
 (c)           |           |   |     | Average         
 Summary         
 Compensation    
 Table Total for 
 Non-PEO Named   
 Executive       
 Officers(3)     
 (d)             |           |     | Average          
 Compensation     
 Actually Paid to 
 Non-PEO Named    
 Executive        
 Officers(2)      
 (e)              |          |   |     | Value of Initial           
 Fixed $100                 
 Investment                 
 Based on Total Shareholder 
 Return(4)                  
 (f)                        |       |     | Net Income     
 (Loss)(5)